ArticleJACC. Advances2026
Sex-Specific Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair: The REPAIR Study.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitral valve transcatheter edge-to-edge repair (M-TEER) is an established treatment for patients with mitral regurgitation (MR) at prohibitive surgical risk. Sex-specific M-TEER outcomes are mainly derived from small, historic, MR etiology-specific, or MitraClip-treated cohorts.
objectivesThe objective of the study was to evaluate sex-specific outcomes in patients undergoing PASCAL M-TEER.
methodsREgistry of PAscal for mItral Regurgitation is an investigator-initiated, multicenter M-TEER registry. Outcomes included Mitral Valve Academic Research Consortium-defined technical success, optimal result at discharge (residual MR ≤ 1+ and mean transmitral pressure gradient <5 mm Hg), and 1-year all-cause mortality.
resultsAmong 2,601 patients, 1,150 (44.2%) were females and 1,451 (55.8%) were males. MR etiology distribution was similar between sexes (primary: 33.5% vs 32.4%; secondary: 48.9% vs 52.1%; mixed: 17.6% vs 15.6%; P = 0.219). Technical success was achieved in 97.0% vs 97.7% (P = 0.395). An optimal result was achieved more often in males (55.7% vs 65.9%; P < 0.001), driven by higher postprocedural gradients in females (mean transmitral valve pressure gradient ≥5 mm Hg: 24.0% vs 14.0%; P < 0.001), whereas residual mild or less MR was similar (71.3% vs 74.6%; P = 0.066). One-year mortality was 11.0% (95% CI: 8.7%-13.2%) vs 12.1% (95% CI: 10.1%-14.1%; P = 0.266). Residual mild or less MR was independently associated with lower 1-year mortality (adjusted HR: 0.57; 95% CI: 0.38-0.84; P = 0.005), whereas gradients <5 mm Hg were not (adjusted HR: 0.63; 95% CI: 0.40-1.01; P = 0.056).
conclusionsPASCAL M-TEER resulted in similar technical success rates and 1-year mortality across sexes, despite females achieving an optimal result less frequently, due to higher postprocedural gradients. MR reduction to mild or less was the primary determinant of improved survival, consistent across sexes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.